Related Experiment Videos

ALS therapy: targets for the future

J Hugon1

  • 1Unit of Neurobiology, UCNRS 1485, Faculty of Medicine, Limoges, France.

Neurology
|December 1, 1996
PubMed

Insights

Amyotrophic lateral sclerosis (ALS) may stem from excitotoxicity, gene mutations, autoantibodies, or neurofilament issues. Combined therapies targeting these mechanisms offer future treatment potential for motoneuron degeneration.

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motoneuron degeneration.
  • Several hypotheses exist regarding the underlying causes of ALS, including excitotoxicity, genetic mutations, autoimmune responses, and protein accumulation.

Purpose of the Study:

  • To review the primary hypotheses concerning the etiology of ALS.
  • To explore potential therapeutic strategies based on these etiological mechanisms.

Main Methods:

  • Literature review of current hypotheses on ALS pathogenesis.
  • Analysis of potential therapeutic targets and combination strategies.

Main Results:

  • Four main hypotheses for ALS causation are identified: glutamate receptor overactivation (excitotoxicity), superoxide dismutase gene mutations, autoantibodies against calcium channels, and neurofilament accumulation.
  • Motoneuron degeneration in ALS may result from one or a combination of these factors.

Conclusions:

  • Future ALS therapies should integrate approaches targeting multiple etiological mechanisms simultaneously.
  • Potential treatments include neuroprotective agents (antiglutamates, NMDA/non-NMDA antagonists, free-radical scavengers, calcium-channel blockers, neurotrophic factors) and gene transfer strategies for identified mutations.

Related Concept Videos